Business
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company announced publication today of abstracts at the 2020 Annual Meeting of the American Association for Cancer Research (AACR).\n\n \n \n \n \n \n \n\n \nThe IDEAYA abstracts were posted online by AACR (http://www.aacr.org) in advance of the AACR Virtual Annual Meeting II, which will be held on June 22-24, 2020:\nTitle: \"Analysis of drug combinations with the PKC inhibitor IDE196 support dual MEK and PKC inhibition as a rational combination in metastatic uveal melanoma\" (Author: Christian Frey) Title: \"MAT2A Inhibitors decrease growth, increase senescence and p53 stability in MTAP-deleted cancer cells\" (Author: Neil Bhola) Title: \"In vitro and in vivo characterization of novel MAT2A allosteric inhibitors\" (Author: Zhonghua Pei)IDE196 is a potent and selective protein kinase C (PKC) inhibitor being evaluated in an ongoing Phase 1/2 tumor-agnostic clinical trial in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) hotspot mutations. IDEAYA is currently enrolling into a Phase 2 monotherapy expansion arm for patients with such GNAQ/11 mutant tumors, including Cutaneous Melanoma, and recently completed enrollment into a Phase 1 monotherapy arm for patients with Metastatic Uveal Melanoma. IDEAYA is preparing to evaluate the clinical combination of IDE196 and binimetinib, a MEK inhibitor, in a combination arm initiating in mid-2020 for patients with such GNAQ/11 hotspot mutations.\n\"We believe that IDE196 presents multiple opportunities for being impactful for patients and creating value. The preclinical combination data with IDE196 and MEK inhibitor being presented at AACR helps guide our clinical development strategy, and demonstrates our commitment to validating these opportunities,\" said Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences. \nIDEAYA's most advanced synthetic lethality program is targeting methionine adenosyltransferase II alpha (MAT2A). IDEAYA plans to develop a MAT2A inhibitor for patients having solid tumors with methylthioadenosine phosphorylase (MTAP) gene deletion, which occurs in approxim...